United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics Corporation (Nasdaq: UTHR) reported record financial results for Q3 2022, achieving revenues of $516.0 million, a 16% year-over-year increase. The net income soared to $239.3 million, a 47% increase from the prior year. Tyvaso emerged as a key revenue driver with sales of $257.7 million, a significant 57% increase year-over-year. The company is advancing clinical studies, including the recently launched TETON 2 study for idiopathic pulmonary fibrosis. The financial results underscore strong growth and successful commercialization strategies.

United Therapeutics Corporation (UTHR) announced that Patrick Poisson, Executive Vice President of Technical Operations, will present at the Credit Suisse 31st Annual Healthcare Conference in Los Angeles. The event is scheduled for November 8, 2022, from 12:50 p.m. to 1:20 p.m. PST. A live webcast will be available on their website, with an archived version accessible for 90 days post-event. United Therapeutics aims to innovate for unmet medical needs, emphasizing their unique position as a public benefit corporation.

United Therapeutics Corporation (Nasdaq: UTHR) announced preliminary results from the EXPEDITE study, which evaluates the efficacy of Remodulin induction in patients with pulmonary arterial hypertension (PAH). In this phase 4 study, 79% of participants achieved a total daily dose of 12 mg of Orenitram after an induction period. The study involved 36 patients, with 29 completing the trial, indicating a significant improvement in dosing efficiency over traditional methods. These findings suggest a potential shift in treatment protocols for PAH.

United Therapeutics Corporation (Nasdaq: UTHR) is set to release its third quarter 2022 financial results on November 2, 2022, before market opening. A public webcast will follow at 9:00 a.m. Eastern Time on the same day, accessible through the company's website. United Therapeutics, a public benefit corporation, focuses on developing innovative pharmaceutical therapies and expanding organ transplant availability. The announcement includes caution about forward-looking statements regarding future operations and potential risks involved.

United Therapeutics Corporation (NASDAQ: UTHR) announced data from the INCREASE and FREEDOM-EV open-label extension studies, showcasing long-term safety for Tyvaso and improved survival in pulmonary arterial hypertension (PAH) patients using Orenitram. Presentations will occur at the CHEST 2022 Annual Meeting, highlighting gaps in initial combination therapy strategies for PAH. Events include the CHEST Women & Pulmonary Luncheon and a symposium on PH-ILD. These findings aim to enhance treatment strategies and outcomes for patients suffering from pulmonary hypertension.

United Therapeutics Corporation (Nasdaq: UTHR) has announced the enrollment of the first patient in the phase 3 TETON 2 study, involving 396 adult patients with idiopathic pulmonary fibrosis (IPF). This 52-week registration study aims to assess the impact of Tyvaso on forced vital capacity (FVC), a key prognostic indicator for IPF. The TETON program further investigates the antifibrotic effects of inhaled treprostinil. IPF is characterized by progressive lung scarring, leading to severe respiratory complications.

United Therapeutics Corporation (NASDAQ: UTHR) released its third annual Corporate Responsibility Report, showcasing its commitment to environmental, social, and governance (ESG) priorities. Highlights include the company's inaugural public benefit report, which emphasizes efforts to develop novel therapies and technologies for organ transplant availability. The report aligns with frameworks like GRI, SASB, and TCFD, and links progress to UN Sustainable Development Goals. The company is recognized as the first publicly traded biotech organized as a public benefit corporation.

United Therapeutics (NASDAQ: UTHR) reported a favorable ruling from the U.S. District Court regarding the infringement of its patents related to treprostinil inhalation. The Court determined that Liquidia Technologies' Yutrepia would infringe the ’793 patent, and an injunction preventing FDA approval until May 14, 2027, is expected. However, the Court invalidated certain claims of the ’066 patent. United Therapeutics plans to evaluate options for appeal regarding the ’066 patent while they continue to defend their intellectual property.